Pharvaris NV (PHVS) Noticias

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE...

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support...

Pharvaris Presents Data at the Bradykinin Symposium 2024

ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities